Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Innovations in Microfluidics & SCA 2021

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology

Prof. Soper (since 2016) is a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$105M, has published over 245 peer-reviewed manuscripts (h index = 67; 16,188 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 48 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.

His major discoveries include: (1) Technology for the detection of circulating tumor cells that can manage a variety of cancer diseases using a simple blood test (test has been demonstrated in multiple myeloma, pediatric acute lymphoblastic leukemia, acute myeloid leukemia, pancreatic, breast, colorectal, prostate, and ovarian cancers); (2) new hardware and assay for the point-of-care diagnosis of acute ischemic stroke; (3) single-molecule DNA and RNA sequencing nanotechnology; and (4) currently working on a home-test for COVID-19 infections (handheld instrument and the associated assay).

Steve Soper Image

Affinity Selection and Enumeration of SARS-CoV-2 Viral Particles from Saliva Samples using Microfluidics for COVID-19 Diagnostics

Thursday, 18 March 2021 at 14:00

Add to Calendar ▼2021-03-18 14:00:002021-03-18 15:00:00Europe/LondonAffinity Selection and Enumeration of SARS-CoV-2 Viral Particles from Saliva Samples using Microfluidics for COVID-19 DiagnosticsInnovations in Microfluidics and SCA 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com

Coronavirus disease 2019 (COVID-19) arises from the SARS-CoV-2 virus and has been found to be highly contagious. To mitigate spreading, testing has been deemed an important asset. Testing has predominately utilized RT-qPCR as well as serological-based tests. However, while new machines are rolling out for point-of-care testing (POCT), issues are present with these common testing systems, for example the need for reagents (e.g. enzymes, fluorescent reporters, antibodies), workflows that sometimes require specialized operators, and the inability to distinguish between infectious and non-infectious individuals, which is important in determining the need for quarantining. We report an innovative COVID-19 diagnostic test that directly addresses the aforementioned issues. The assay accepts a clinical sample and specifically selects SARS-CoV-2 particles from the sample using surface-immobilized DNA aptamers targeting the spike protein, releases photolytically the selected viral particles (VPs), and then counts the number of SARS-CoV-2 particles using a label-free approach. The workflow is simple and fully automated and also, no reagents are required once the assay is deployed for testing. The entire assay was carried out using microfluidic chips made from a plastic that were injection molded to allow for high scale production at low cost. The VP selection chip consisted of 1.5 million pillars that allowed for affinity loading up to 1010 SARS-CoV-2 particles at a recovery ~90%. Following selection, the VPs were released from the capture surface using a photocleavable linker by a blue-light LED (79% release efficiency) and subsequently counted using a nano-Coulter Counter (nCC). For high throughput single VP counting, 5 nCCs were placed in parallel and offered 100% detection efficiency for VPs travelling through a 200 nm pore. The entire assay could be completed in <20 min. In a 20 patient blinded study, the test correctly identified 10 non-infected individuals (clinical specificity = 100%) and in 5 COVID-19 patients, VPs were detected indicative of “active” disease, while 4/5 others were deemed infected by RT-qPCR, but those individuals had no VPs suggesting these patients were not contagious (clinical sensitivity = 95%).


Add to Calendar ▼2021-03-18 00:00:002021-03-19 00:00:00Europe/LondonInnovations in Microfluidics and SCA 2021Innovations in Microfluidics and SCA 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com